JAGX stock forecast, quote, news & analysis

Key Takeaways

• Jaguar Health (JAGX) shares have fallen roughly 70% over the last 30 days, extending a steep multi-month downtrend.
• The decline follows a 1-for-15 reverse stock split effective September 17, 2026, executed to support Nasdaq listing compliance.
• A brief September 22 spike tied to an FDA fee waiver for Mytesi reversed quickly amid profit-taking and renewed equity dilution.
• Debt-for-equity exchanges with lender Streeterville Capital reduced debt but expanded the share count, pressuring the stock.
• Ongoing going-concern risk, a roughly $391 million accumulated deficit, and a $12.7 million Q2 2026 net loss continue to weigh on sentiment.
• For deeper data on this ticker, review its Price Targets, Earnings, and Forecast pages.
• Explore automated trading strategies on the Trending AI Robots page.

Jaguar Health (JAGX) Company Overview and Market Position

Jaguar Health, Inc. is a San Francisco-based commercial-stage biopharmaceutical company developing plant-derived prescription medicines for gastrointestinal conditions. Its lead compound, crofelemer, is purified from the red bark sap of the Croton lechleri tree and is the active ingredient in Mytesi, an FDA-approved treatment for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, and in Canalevia-CA1, conditionally approved for chemotherapy-induced diarrhea in dogs.

In January 2026, Jaguar out-licensed U.S. commercialization of Mytesi and Canalevia-CA1 to an affiliate of Future Pak, receiving a $16 million upfront fee (up to $18 million including post-closing conditions) plus up to $20 million in milestone payments. The company has since concentrated its development efforts on a concentrated liquid formulation of crofelemer for rare intestinal failure indications, including microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). Investors follow the stock for its rare-disease pipeline catalysts as well as its liquidity and dilution risks.

Jaguar Health (JAGX) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, JAGX has declined approximately 70%, from an adjusted closing price near $7.70 in late September to about $2.28. The move was volatile rather than linear: shares spiked above $34 intraday in late September before giving back most of those gains within days.

The broader trend is even steeper. Over the trailing three months, the stock has fallen roughly 85%, from about $15.00 in late July to current levels. The 1-for-15 reverse stock split that took effect on September 17, 2026 was a mechanical adjustment that consolidated shares without changing market capitalization, but the continued slide that followed reflects persistent dilution and concerns about the company's balance sheet.

What Drove JAGX Stock Price in the Last 30 Days

The recent 30-day move was dominated by capital-structure changes and extreme low-float volatility. On September 17, 2026, Jaguar completed a 1-for-15 reverse stock split to regain compliance with Nasdaq's minimum bid-price requirement, leaving a public float of roughly 520,000 shares.

On September 22, the stock surged more than 1,100% to close near $34.46 after the FDA granted a fiscal year 2027 Prescription Drug User Fee Act (PDUFA) fee waiver for Mytesi. The constrained float amplified the move. The rally reversed over the following sessions as profit-taking set in and the company disclosed debt-for-equity exchanges with Streeterville Capital, issuing 547,898 new shares to retire about $5.05 million of its secured 2025 promissory note, a roughly 42.7% expansion of the then-outstanding share count. Additional exchanges in late September fully retired the note, reducing total debt by more than $6.7 million but further diluting existing holders. A Form 424B5 prospectus supplement filed on September 3 had already signaled the potential for further equity issuance.

What Drove JAGX Stock Performance Over the Last Quarter

Over the trailing quarter, the overriding narrative has been balance-sheet pressure rather than a single catalyst. Jaguar reported a second-quarter 2026 net loss of approximately $12.7 million against roughly $1.2 million in net prescription product revenue, underscoring continued cash burn. The company's filings disclose an accumulated deficit of about $391.1 million as of March 31, 2026 and state that recurring losses raise substantial doubt about its ability to continue as a going concern.

The strategic shift toward rare-disease development, while potentially transformative, has left the company dependent on additional financing ahead of its planned mid-2027 new drug application for crofelemer in MVID. That combination of dilution, thin liquidity, and uncertain funding has kept shares under sustained downward pressure over the quarter.

Trending AI Robots

Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots drawn from a broader platform that operates hundreds of bots across thousands of tickers. Only top-performing and most relevant bots appear in this featured section, helping traders filter through the full universe of strategies. The bots vary in approach, holding timeframe, and performance metrics, so the page is designed to let users compare and identify strategies that align with their own objectives. Traders exploring highly volatile names such as JAGX can review the section to see which automated approaches are currently gaining traction.

JAGX Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, the key factors for JAGX include the timing and outcome of its planned new drug application for crofelemer in MVID, targeted for mid-2027, and whether the company secures Breakthrough Therapy designation from the FDA. Additional Phase 2 data in SBS-IF and any partnership or business-development announcements could also shape the outlook. On the risk side, investors should monitor financing and dilution events, the company's cash runway, and its ability to maintain Nasdaq listing compliance. Given the company's going-concern disclosure, liquidity and capital-raising activity remain central to the stock's trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations